Central procurement of pharmaceutical consumables has been carried out for 5 years
Cumulatively reduce the cost of drug consumption by more than 400 billion yuan (new data and new highlights)
Our newspaper, Beijing, February 4th (Reporter Sun Xiuyan) The reporter learned from the National Medical Security Work Conference held recently: In 2022, the National Medical Insurance Administration will continue to promote the centralized procurement of pharmaceutical consumables, and the average price of the seventh batch of centralized procurement of pharmaceuticals will be reduced by 48%. The average price of consumable centralized procurement products was reduced by 84%, and the result of the centralized procurement of insulin was implemented, benefiting more than 10 million patients.
Taking lenvatinib capsules, a first-line targeted drug for liver cancer, as an example, the average price per capsule has dropped from 108 yuan to 18 yuan, which can save 8,100 yuan in one treatment cycle.
In the field of blood pressure reduction, sustained and controlled-release dosage forms were included for the first time. The price of nifedipine controlled-release tablets was reduced by 58%, and the price of metoprolol sustained-release tablets was reduced by 53%. The burden of medication for hypertensive patients was significantly reduced.
According to reports, since the establishment of the National Medical Insurance Bureau in 2018, it has continued to squeeze the falsely high prices of pharmaceutical consumables. The national organization has collected 7 batches of 294 kinds of drugs with an average price reduction of more than 50%, and the average price reduction of 3 batches of 4 types of consumables has exceeded 80%; superimposed local alliances Centralized procurement has reduced drug consumption by more than 400 billion yuan.
The proportion of patients who use high-quality medicines from centrally-purchased varieties has increased from 50% to more than 90%.
While the sense of gain of the majority of insured people continues to increase, the space for "sales with gold" of drugs continues to be compressed, and more and more drug manufacturers are embarking on a new development path that emphasizes innovation and quality.
At the same time, the price of new drugs has been reduced through negotiations. The average price of 250 new drugs has been reduced by more than 50% and included in medical insurance reimbursement, so that the masses can use drugs that they could not afford before.
At present, the number of drugs in the national medical insurance catalog has increased by 618 compared with 2017, and the drug price index has dropped for five consecutive years.
In 2023, the National Medical Insurance Administration will continue to carry out new batches of state-organized centralized procurement of drugs and high-value medical consumables, expand the coverage of local centralized procurement, and achieve a total of 450 national and provincial centralized procurement of drugs.